Conference Coverage
Conference Coverage
Advertisement
Andrew MorenoASH 2024 | December 20, 2024
An MDS HSPC signature generated from the model presents possible targets for treatment in patients with low-risk disease.
Read More
Andrew MorenoASH 2024 | December 20, 2024
The study's results especially highlight potential aberrant gene regulation by ZMAT2 and SMARCD3.
Andrew MorenoASH 2024 | December 20, 2024
The study showed a mortality risk reduction benefit in certain mutations while for others larger studies are needed.
Andrew MorenoASH 2024 | December 20, 2024
Researchers noted that confirmation of this relationship in lower-risk disease would require a larger study.
Karine Tawagi, MDSABCS 2024 | December 19, 2024
Dr. Karine Tawagi speaks with Dr. Adam Brufsky about notable data presented at SABCS 2024.
Karine Tawagi, MDSABCS 2024: Expert on Site | December 19, 2024
Dr. Adam Brufsky provides an overview on the best treatments in metastatic TNBC space, including Trodelvy.
Karine Tawagi, MDSABCS 2024: Expert on Site | December 19, 2024
Drs. Karine Tawagi and Adam Brufsky discuss the challenges of navigating treatment in patients with mTNBC.
Rob DillardSABCS 2024: Expert on Site | December 19, 2024
A study sought to assess if a treatment combination inhibits tumor growth and metastasis in TNBC.
Rob DillardSABCS 2024: Expert on Site | December 18, 2024
Sacituzumab govitecan-related neutropenia can be effectively treated using G-CSF prophylaxis in patients with mTNBC.
Andrew MorenoASH 2024 | December 18, 2024
Researchers argue from their findings that the 2023 criteria more accurately present the performance of ivosidenib in MDS.
Andrew MorenoASH 2024 | December 18, 2024
The combination in a phase II trial produced high complete response rates in patients with newly diagnosed AML.
Andrew MorenoASH 2024 | December 18, 2024
Researchers also analyzed baseline stem cells for insight into patient response versus non-response to the combination.
Andrew MorenoASH 2024 | December 18, 2024
The combination was compared with decitabine monotherapy in a multicenter, open-label, RCT.
Patrick DalyASH 2024 | December 16, 2024
A study evaluated azacitidine combined with ipilimumab or nivolumab and triplet of these agents in treatment-naive MDS.
Rob DillardAHA 2024: CardioNerds | December 13, 2024
A study shows how how advancements in diagnostic tools and treatments for ATTR-CM have improved risk profiles.
Rob DillardAHA 2024: CardioNerds | December 13, 2024
A recent post-hoc analysis of the ATTRibute-CM trial shows the potential for acoramidis in treating ATTR-CM.
Rob DillardAHA 2024 | December 13, 2024
A study found an overall decline in surgical myectomy with ICD procedures since 2016.
Rob DillardSABCS 2024 | December 12, 2024
Researchers sought to assess the rate of axillary pCR in TNBC patients.
Andrew MorenoASH 2024 | December 12, 2024
Across several patient subgroups luspatercept was observed to produce longer durations of transfusion independence.
Rob DillardSABCS 2024 | December 12, 2024
Adding pembrolizumab to conventional neoadjuvant cytotoxic chemotherapy may improve survival outcomes.
Advertisement
Advertisement
Advertisement
Latest News

December 26, 2024